Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 18, 24 | -0.37 Decreased by -32.14% | -0.26 Decreased by -42.31% |
| Nov 13, 23 | -0.24 Increased by +25% | -0.27 Increased by +11.11% |
| Aug 11, 23 | -0.28 Decreased by -7.69% | -0.27 Decreased by -3.7% |
| May 12, 23 | -0.25 Increased by +3.85% | -0.29 Increased by +13.79% |
| Mar 15, 23 | -0.28 Decreased by -27.27% | -0.35 Increased by +20% |
| Nov 10, 22 | -0.32 Decreased by -52.38% | -0.28 Decreased by -14.29% |
| Aug 12, 22 | -0.26 Increased by +54.39% | -0.33 Increased by +21.21% |
| May 10, 22 | -0.26 Increased by +45.83% | -0.33 Increased by +21.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by N/A% | -5.11 M Decreased by -351.78% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by N/A% | -3.11 M Increased by +12.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -3.45 M Decreased by -31.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -2.9 M Decreased by -8.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | 2.03 M Increased by +177.32% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -3.54 M Increased by +23.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -2.62 M Increased by +34.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -2.67 M Decreased by -81.11% | Decreased by N/A% Decreased by N/A% |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.